Neuropathic pain: targeting the melatonin MT2 receptor
South African Family Practice
| Field | Value | |
| Title | Neuropathic pain: targeting the melatonin MT2 receptor | |
| Creator | Smith, N. Ismail, H. Schellack, N. | |
| Description | Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDS and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT2 receptor has also been specifically linked to the control of neuropathic pain and inflammation. | |
| Publisher | AOSIS | |
| Date | 2016-08-04 | |
| Identifier | 10.4102/safp.v58i4.4528 | |
| Source | South African Family Practice; Vol 58, No 4 (2016): July/August; 31-34 2078-6204 2078-6190 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://safpj.co.za/index.php/safpj/article/view/4528/5376
|
|
ADVERTISEMENT
